Results 251 to 260 of about 578,217 (295)

A study of muscarinic receptor heterogeneity with weak antagonists

European Journal of Pharmacology, 1976
A study of heterogeneity among muscarinic receptors was carried out with new rigid molecules, comprising structures in the fused quinuclidine-valerolactone, quinuclidine-cyclohexenone, quinuclidine-cyclohexanone and quinuclidine-cyclohexane derivatives.
A, Fisher, Y, Grunfeld, M, Weinstock, S, Gitter, S, Cohen   +4 more
openaire   +2 more sources

Identification and characterization of m4 selective muscarinic antagonists

Bioorganic & Medicinal Chemistry Letters, 1997
Our interest in the area of m4 muscarinic antagonists had led us to study a series of benzoxazine isoquinolines. One of the most potent and selective compounds of this series is example 1 with an IC50 value of 90.7 nM at m4 receptors, and 72-fold (m1), 38-fold (m2), 10-fold (m3), and 82-fold (m5) more selective compared to the other receptors.
C E, Augelli-Szafran, J C, Jaen, D W, Moreland, C B, Nelson, J R, Penvose-Yi, R D, Schwarz   +5 more
openaire   +2 more sources

Muscarinic Receptor Subtypes and the Selectivity of Agonists and Antagonists

Pharmacology, 1988
Receptors may be grouped into superfamilies, according to their mechanism. Muscarinic receptors belong to one such superfamily, that of the G-protein coupled receptors. Subtypes of muscarinic receptors may be defined according to their primary amino acid sequence, their mechanism and their pharmacology.
N J, Birdsall, C A, Curtis, P, Eveleigh, E C, Hulme, E K, Pedder, D, Poyner, M, Wheatley   +6 more
openaire   +2 more sources

The discovery of AZD9164, a novel muscarinic M3 antagonist

Bioorganic & Medicinal Chemistry Letters, 2011
The optimization of a new series of muscarinic M(3) antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.
Antonio, Mete, Keith, Bowers, Eric, Chevalier, David K, Donald, Helen, Edwards, Katherine J, Escott, Rhonan, Ford, Ken, Grime, Ian, Millichip, Barry, Teobald, Vince, Russell   +10 more
openaire   +2 more sources

Muscarinic Receptor Antagonists

Pulmonary Pharmacology & Therapeutics, 1999
N, Watson, R M, Eglen
openaire   +2 more sources

[Antianaphylactic effects of muscarinic antagonists].

Eksperimental'naia i klinicheskaia farmakologiia, 2010
The study was carried out on color guinea pigs, in which anaphylactic shock was induced by sensitizing and challenging doses of normal horse serum (HS). Administration of atropine, ipratropium, or ipratropium in combination with neostigmine led to reduction of sensitizing effect of HS: anaphylactic index was decreased up to (2.2 - 2.4) +/- 0.1 ...
G I, Nezhinskaia, A L, Vladykin, N S, Sapronov   +2 more
openaire   +1 more source

Muscarinic Agonists and Antagonists: Effects on the Urinary Bladder

2011
Voiding of the bladder is the result of a parasympathetic muscarinic receptor activation of the detrusor smooth muscle. However, the maintenance of continence and a normal bladder micturition cycle involves a complex interaction of cholinergic, adrenergic, nitrergic and peptidergic systems that is currently little understood.
Sellers, Donna J., Chess-Williams, Russ
openaire   +2 more sources

Synthesis of novel and functionally selective non‐competitive muscarinic antagonists as chemical probes

Chemical Biology and Drug Design, 2018
John Boulos, J. Jakubík, John Boulos, Alena Randáková, Jelena Momirov   +4 more
semanticscholar   +1 more source

THE INTERACTION OF NICOTINIC RECEPTOR ANTAGONISTS AT MUSCARINIC RECEPTORS

Clinical and Experimental Pharmacology and Physiology, 1987
SUMMARY1. The interaction of some neuromuscular blocking drugs such as gallamine, pancuronium and stercuronium with muscarinic receptors has several features which distinguish these compounds from competitive antagonists in functional and binding studies.2. They also differentiate between muscarinic receptors and may produce effects on ion channels.
openaire   +2 more sources

Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Expert Opinion on Investigational Drugs, 2017
Mark A. Mastrodicasa, C. Droege, Aaron M Mulhall, N. Ernst, R. Panos, M. Zafar   +5 more
semanticscholar   +1 more source